Zetiq and Biomics Biotechnologies will collaborate on the development and commercialization of Zetiq's CellDetect technology for early-stage cancer diagnosis.
Bio-Light Israeli Life Sciences Investments Ltd. (TASE:BOLT) portfolio company Zetiq Technologies Ltd., has signed a memorandum of understanding (MOU) with China's Biomics Biotechnologies Company Ltd. to collaborate on the development and commercialization of Zetiq's CellDetect technology for early-stage cancer diagnosis.
Zetiq and Biomics will adapt CellDetect for the Chinese market and to obtain regulatory approval for the product within two years from the signing of a binding contract. Biomics will handle the registration process with the Chinese State Food and Drug Administration, while Zetiq will provide CellDetect components and assist in the registration process.
Published by Globes [online], Israel business news - www.globes-online.com - on December 1, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009